Clinical Trials Browser

OTHER × Has results × Brentuximab Vedotin × Clear all

NCT01920932 2025-12-03

Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma

Phase 2 Active not recruiting

77 enrolled 20 charts

Hodgkin Disease, Neoplasms

NCT02588651 2025-11-21

A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

Phase 2 Completed

23 enrolled 15 charts

LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Leukemia, Lymphoma, Lymphoma, T-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT02227199 2025-11-18

BV-ICE

Phase 1/2 Completed

45 enrolled 14 charts

Hodgkin Disease

NCT03113500 2025-11-14

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

Phase 2 Active not recruiting

48 enrolled 8 charts

LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Enteropathy-Associated T-Cell Lymphoma

NCT01508312 2025-10-21

Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 2 Completed

66 enrolled 14 charts

Hodgkin Disease

NCT03057795 2025-05-07

Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma

Phase 2 Active not recruiting

62 enrolled 8 charts

Hodgkin Disease

NCT02744612 2025-03-26

Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 2 Completed

39 enrolled 9 charts

Hodgkin Disease

NCT03264131 2025-02-10

BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma

Phase 2 Active not recruiting

16 enrolled 8 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphatic Diseases, Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02388490 2024-09-23

Bretuximab

Phase 2 Completed

25 enrolled 12 charts

Lymphoma, Recurrence

NCT02096042 2023-10-10

Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)

Phase 1/2 Terminated

1 enrolled 3 charts

Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT02429375 2022-05-12

Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 1/2 Completed

7 enrolled 10 charts

Hodgkin Disease, Recurrence

NCT01578967 2021-12-07

Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma

Phase NA Completed

41 enrolled 14 charts

Hodgkin Disease

NCT01805037 2021-09-01

Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas

Phase 1/2 Terminated

20 enrolled 17 charts

DermatologicLymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Epstein-Barr Virus Infections, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Intraocular Lymphoma

NCT02988843 2020-12-10

Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors

Phase 2 Terminated

1 enrolled 8 charts

Neoplasms, Germ Cell and Embryonal

NCT02505269 2020-08-24

Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma

Phase 2 Completed

34 enrolled 7 charts

Hodgkin Disease

NCT02689219 2019-12-10

Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors

Phase 2 Terminated

18 enrolled 13 charts

Nonseminomatous germ cell tumor, Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms, Carcinoma, Embryonal

NCT02169505 2019-11-27

Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)

Phase 2 Terminated

2 enrolled 5 charts

Graft vs Host Disease, Hodgkin Disease, Lymphoma, Lymphoma, Large-Cell, Anaplastic

NCT01807598 2019-01-29

Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia

Phase 2 Completed

10 enrolled 14 charts

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT01393717 2018-04-26

Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma

Phase 2 Completed

57 enrolled 14 charts

Hodgkin Disease

NCT01534078 2018-02-20

Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma

Phase 2 Completed

34 enrolled 15 charts

Hodgkin Disease

NCT01396070 2017-04-05

Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level

Phase 2 Completed

36 enrolled 13 charts

DermatologicLymphoid

Lymphoma, Non-Hodgkin, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT01841021 2017-01-19

Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30

Phase NA Terminated

1 enrolled 5 charts

Recurrence, Lymphoma, T-Cell, Peripheral